Agave Health
Virtual clinic providing comprehensive ADHD care for adults through coaching, therapy, diagnosis, and tools.
Website: https://www.agavehealth.com
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Name | Agave Health |
| Tagline | Virtual clinic providing comprehensive ADHD care for adults through coaching, therapy, diagnosis, and tools |
| Headquarters | New York City, United States |
| Founded | 2022 |
| Stage | Seed |
| Business Model | B2C (with employer-sponsored option) |
| Industry | Healthtech / Behavioral Health |
| Technology Type | Software (Non-AI) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2): Eve Lise Mamane, Ori Fruhauf |
| Funding Label | Seed |
Links
PUBLIC
- Website: https://www.agavehealth.com
- LinkedIn: https://www.linkedin.com/company/agave-health
Executive Summary
PUBLIC
Agave Health is a New York-based virtual clinic built specifically for adults living with ADHD, packaging diagnosis, therapy, coaching, and self-directed tools into a single membership product [Agave Health]. The company was founded in 2022 by Eve Lise Mamane and Ori Fruhauf and has raised seed capital from Good Company and SeedIL Ventures [Tracxn, 2025] [CB Insights]. Adult ADHD has historically been routed through general psychiatry waitlists or stimulant-first telehealth providers. Agave's pitch is that a condition-specific care home, with both clinical evaluation and ongoing behavioral coaching, is a better fit for how the disorder actually presents in adulthood [Agave Health]. The membership bundles a clinical survey, therapist analysis, two 45-minute virtual therapy sessions, and a 30-minute evaluation outcome session that produces a recommended treatment path [Agave Health]. Clinical credibility is anchored by an advisory bench that includes Dr. Singh, formerly Chief Behavioral Science Officer at Dario Health following the acquisition of her prior startup wayForward, who advises on clinical product [Agave Health]. The company also offers an employer-sponsored channel, where companies can underwrite employee subscriptions via a company code at checkout [Agave Health]. Over the next 12 to 18 months, the questions worth tracking are whether Agave can convert its consumer membership funnel into a repeatable employer-benefits motion, how it positions against the wave of ADHD-adjacent telehealth providers that emerged during the pandemic, and whether the seed round is followed by a priced Series A that would validate retention economics.
Data Accuracy: GREEN -- Confirmed by company website, Tracxn (2025), Crunchbase, and CB Insights.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | B2C, with employer-sponsored channel |
| Industry / Vertical | Healthtech, adult behavioral health (ADHD) |
| Technology Type | Software (Non-AI) |
| Geography | North America (HQ New York City) |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Seed (Good Company, SeedIL Ventures) |
Company Overview
PUBLIC
Agave Health was founded in 2022 in New York City by Eve Lise Mamane and Ori Fruhauf with the stated mission of providing "comprehensive and affordable care to every adult with ADHD" [Agave Health]. The company describes itself externally as "the first virtual clinic for adults with ADHD, providing comprehensive behavioral care accessible to all" [LinkedIn]. The framing matters because most adult ADHD care in the United States has historically been delivered either through episodic psychiatry visits or through telehealth providers oriented around medication management. Agave positions itself instead as a continuous-care home that combines clinical assessment with ongoing behavioral coaching.
Mamane has spoken publicly about the founding rationale, including in a Calcalist (Ctech) interview where she discussed building the company as a female founder in healthtech [Ctech]. Fruhauf is listed as co-founder across third-party databases including Tracxn [Tracxn, 2025]. The company is incorporated in the United States as Agave Health INC, with a separate LinkedIn presence reflecting an Israel-linked footprint, consistent with the involvement of SeedIL Ventures, an Israeli early-stage investor [LinkedIn] [StartupHub.ai].
Public milestones since founding are sparse in the structured record: incorporation and product launch in 2022, a seed financing involving Good Company and SeedIL Ventures, and the build-out of a coaching team and clinical advisory bench that includes Dr. Singh in an advisory capacity on clinical product [Agave Health] [Tracxn, 2025] [CB Insights]. There is no publicly disclosed Series A as of the source set reviewed.
Data Accuracy: GREEN -- Confirmed by Agave Health company site, Tracxn (2025), LinkedIn, and Ctech.
Product and Technology
MIXED
Agave's consumer-facing product is a single membership plan that bundles assessment and ongoing care [PUBLIC]. According to the membership page, the price covers "the individual completion of a clinical survey, its analysis by your therapist, two 45-minutes synchronous virtual sessions with your therapist, as well as one 30-minutes synchronous session focused on providing your with your evaluation's outcome and a recommended treatment path" [Agave Health]. Beyond the initial evaluation arc, the company markets ADHD coaching as an ongoing modality, with named coaches such as CJ Pringle and Becca Branham producing content on themes including working memory in conversations, emotional regulation, and end-of-year overwhelm [Agave Health]. The product is described as a "care home base: coaching, therapy, diagnosis, and tools designed around how your brain actually works" with the explicit promise of "no waitlists" [Agave Health].
The employer channel is a parallel distribution path rather than a separate product. The support page instructs that "if your employer sponsors your Agave Health subscription, you can insert your company code upon purchase to access all our care modalities" [Agave Health]. This implies a code-redemption flow rather than a fully integrated benefits-administration integration, which is notable for diligence on the B2B2C motion.
Technology disclosures are minimal [PRIVATE]. There are no surfaced job postings in the captured set from which to infer a stack. Clinical content and coaching IP, rather than proprietary machine learning, appear to be the differentiation the company is currently leaning on, with Dr. Singh advising on clinical product following her tenure as Chief Behavioral Science Officer at Dario Health (NASDAQ: DRIO) after the acquisition of her prior startup wayForward [Agave Health].
Data Accuracy: GREEN -- Confirmed by Agave Health membership, support, and care-team pages.
Market Research and Opportunity
PUBLIC
Adult ADHD care has moved from a niche clinical specialty to a mainstream digital health category over the past five years. The demand-side question is no longer whether the market exists but who serves it responsibly. Awareness of adult ADHD has risen sharply, telehealth prescribing rules adopted during the COVID-19 public health emergency expanded virtual access to controlled-substance evaluations, and consumer willingness to pay out of pocket for behavioral health subscriptions has been demonstrated by adjacent categories such as therapy marketplaces and meditation apps.
No third-party TAM, SAM, or SOM figures for adult ADHD care are present in the captured source set, and Agave itself does not publish a sizing claim. The public record does establish competitive density: Tracxn reports that Agave operates in a category with 333 active competitors providing virtual therapy and coaching for ADHD adults [Tracxn, 2025]. That figure is the most concrete market signal available, and it cuts in two directions, validating that capital and founders see a real opportunity while flagging that differentiation will be hard-fought.
| Sizing claim | Value | Source |
|---|---|---|
| Active competitors in virtual ADHD therapy and coaching | 333 | [Tracxn, 2025] |
The category is crowded enough that distribution and clinical credibility, rather than the existence of demand, are the binding constraints. A field of 333 competitors implies that consumer acquisition cost and employer-channel access are likely to be the main battlegrounds.
Regulatory and macro forces deserve attention. The post-pandemic unwinding of telehealth flexibilities for controlled-substance prescribing has been the defining policy story for adult ADHD telehealth, repeatedly extended by the U.S. Drug Enforcement Administration. Agave's positioning around therapy, coaching, and diagnosis (rather than a stimulant-first prescribing model) reduces its direct exposure to that regulatory cycle, though it also means the company is not capturing the medication-management revenue that some competitors monetize. Adjacent and substitute markets include general adult telepsychiatry, employer EAPs, ADHD-specific medication telehealth, and a growing category of self-directed digital tools and apps. Each represents both a competitive threat and a potential channel partner.
Data Accuracy: YELLOW -- Single-source competitor count from Tracxn (2025); no third-party TAM cited.
Competitive Landscape
MIXED
Agave is positioned as a condition-specific virtual clinic in a category dominated on one side by horizontal telehealth platforms and on the other by stimulant-prescribing telehealth specialists.
The segment map has three layers worth distinguishing [PUBLIC]. The first is horizontal teletherapy and telepsychiatry incumbents, large platforms that treat ADHD as one of many conditions and benefit from broad payer contracts and consumer brand recognition. The second is ADHD-focused telehealth providers that emerged during the pandemic to deliver fast-track diagnosis and stimulant prescriptions; this segment has faced the most regulatory scrutiny and the most volatile public narrative. The third is the coaching and self-directed-tools layer, which includes independent ADHD coaches, community products, and consumer apps. Agave's pitch is that it integrates clinical evaluation with ongoing coaching in a way that none of the three segments does cleanly on its own [Agave Health].
Where Agave has a defensible edge today, the strongest candidate is clinical-product credibility tied to its advisory bench [MIXED]. Dr. Singh's prior role as Chief Behavioral Science Officer at Dario Health following the wayForward acquisition gives the clinical product line a credentialed lineage that not every coaching-led competitor can match [Agave Health]. The named coach roster, with public-facing content under attributed bylines, also functions as a trust signal that anonymous-marketplace competitors cannot easily replicate [Agave Health]. These are perishable rather than durable advantages, however: clinical advisors can be hired by anyone with a budget, and content marketing scales with capital.
Where Agave is most exposed is distribution. The captured sources do not show payer contracts, large employer customers by name, or a partnership with a national benefits broker. Competitors with established employer-benefits integrations or in-network insurance status can put themselves in front of millions of covered lives in a way that a code-redemption employer flow cannot match at scale [Agave Health]. Over the next 18 months, the most plausible competitive scenario is bifurcation: Agave wins if it converts its clinical credibility into two or three anchor employer or health-plan contracts that validate the B2B2C motion, and it loses ground if a better-capitalized horizontal teletherapy platform launches a credible ADHD-specific product line and bundles it into existing payer relationships.
Data Accuracy: YELLOW -- Competitor count confirmed by Tracxn (2025); no named peer comparison available in public sources.
Opportunity
PUBLIC
If Agave executes, the prize is becoming the default condition-specific care home for adult ADHD in the United States, a category that today has no clear consumer brand winner.
The headline opportunity
The single largest outcome Agave could plausibly become is the Livongo-for-ADHD: a vertically focused behavioral-health platform that owns the relationship with the adult ADHD patient across diagnosis, therapy, coaching, and ongoing self-management, and then sells that integrated care into employers and health plans as a measurable benefits product. The evidence that this is reachable rather than aspirational rests on three observations from the cited record. First, the category has demonstrated venture appetite, with 333 active competitors validating that capital is flowing into virtual ADHD care [Tracxn, 2025]. Second, the company has assembled clinical-product leadership with a prior digital-health exit, in the form of Dr. Singh's wayForward-to-Dario Health track record [Agave Health]. Third, Agave has already built the dual-channel architecture, consumer membership plus employer-sponsored code redemption, that a vertical behavioral-health platform requires to scale beyond direct-to-consumer economics [Agave Health].
Growth scenarios
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Employer-benefits anchor | Agave signs two or three Fortune 1000 employers as sponsoring customers, validating the B2B2C motion and generating a repeatable benefits-broker pipeline | A named employer launch, ideally one with a public neurodiversity-at-work program | The employer code-redemption flow is already live on the support page [Agave Health] |
| Clinical-content category leadership | Agave's coaching roster and blog become the highest-trust consumer destination for adult ADHD content, lowering CAC and creating an inbound funnel that competitors cannot match on cost | Sustained content cadence from named coaches such as CJ Pringle and Becca Branham, plus advisor-driven clinical credibility | Named coach content and an active blog are already in market [Agave Health] |
| Health-plan or DTx pathway | A regional health plan contracts Agave as an in-network behavioral-health benefit for adult ADHD members, or the company pursues a digital-therapeutic regulatory pathway for one of its programs | A pilot with a Blues plan or a regional payer | Adjacent precedent in digital behavioral health following Dr. Singh's wayForward-to-Dario Health path [Agave Health] |
What compounding looks like
The flywheel that turns one win into the next has three loops. The clinical-content loop converts blog and coach-authored material into low-CAC consumer signups, which produce outcomes data that strengthens the pitch to employers. The employer loop converts each anchor customer into a reference account that compresses the sales cycle for the next, particularly when sponsored employees become advocates inside their own networks. The coach-supply loop is the most underrated: a named, public-facing coach roster is both a trust signal to consumers and a recruiting magnet for additional clinicians, which is the binding capacity constraint in any virtual-care model. Early evidence that the first loop is starting includes the active blog cadence and the named-coach content surfaced in the captured sources [Agave Health].
The size of the win
A credible directional comparable is Dario Health (NASDAQ: DRIO), the public digital-health company that acquired Dr. Singh's prior startup wayForward and where she subsequently served as Chief Behavioral Science Officer [Agave Health]. The relevant point is not Dario's current market capitalization, which fluctuates, but the category precedent: a vertically focused digital behavioral-health asset can become a public-company line of business, and the path from seed-stage virtual clinic to acquired or independently scaled platform has been walked before in adjacent conditions. If Agave reaches the employer-anchor scenario above, the plausible outcome range is a strategic acquisition by a horizontal teletherapy platform, a benefits navigator, or a public digital-health company seeking a condition-specific product line (scenario, not a forecast).
Data Accuracy: YELLOW -- Scenarios grounded in cited product, team, and category evidence; outcome ranges are explicitly framed as scenarios.
Sources
PUBLIC
[Agave Health] Comprehensive ADHD Care for Adults | https://www.agavehealth.com
[Agave Health] One Membership, Holistic ADHD Care | https://www.agavehealth.com/about-us
[Agave Health] One Membership Plan | https://www.agavehealth.com/membership
[Agave Health] Contact and ADHD Care FAQs | https://www.agavehealth.com/support
[Agave Health] Meet the Care Team and ADHD Coaches | https://www.agavehealth.com/care-team
[Agave Health] Meet the Coaches: CJ Pringle | https://www.agavehealth.com/post/meet-the-coaches-cj-pringle
[Agave Health] ADHD Emotional Overwhelm blog post | https://www.agavehealth.com/post/adhd-emotional-overwhelm-turn-feelings-into-focus-through-q4-holidays-and-financial-stress
[Agave Health] Comprehensive ADHD Care for Adults, Employers page | https://www.agavehealth.com/employers
[LinkedIn] Agave Health company page | https://www.linkedin.com/company/agave-health
[Tracxn, 2025] Agave Health 2025 Company Profile, Team, Funding and Competitors | https://tracxn.com/d/companies/agave-health/__20CRG4Va_i1xLko4eeIW7mfnvRt3HG8YnZMctCE1Q-Q
[Tracxn, 2025] Agave Health 2025 Funding Rounds and List of Investors | https://tracxn.com/d/companies/agave-health/__20CRG4Va_i1xLko4eeIW7mfnvRt3HG8YnZMctCE1Q-Q/funding-and-investors
[Crunchbase] Agave Health Company Profile and Funding | https://www.crunchbase.com/organization/agave-health
[PitchBook, 2026] Agave Health 2026 Company Profile | https://pitchbook.com/profiles/company/519240-97
[CB Insights] Agave Health Stock Price, Funding, Valuation, Revenue and Financial Statements | https://www.cbinsights.com/company/agave-health/financials
[StartupHub.ai] SeedIL Ventures investor profile | https://www.startuphub.ai/investors/seedil-ventures/
[Ctech] Interview featuring Agave Health co-founder Eve Mamane | https://www.calcalistech.com/ctechnews/article/byiuc0gqc
Articles about Agave Health
- Agave Health Is Building a Virtual Clinic for Every Adult Stuck on an ADHD Waitlist — The New York seed-stage startup bundles diagnosis, therapy, and coaching into one membership for adults who often wait months to see a specialist.